1. Introduction {#S1}
===============

Trachoma is the leading infectious cause of blindness worldwide([@R1]). Mass, community-wide, oral azithromycin treatments have proven effective in reducing the prevalence of the causative agent, *Chlamydia trachomatis*([@R2]; [@R3]; [@R4]; [@R5]; Gebre et al., 2011). Hygiene programs and latrine construction are also thought to reduce transmission ([@R7]). In some areas, infection is disappearing even in the absence of a dedicated treatment program ([@R3]; [@R8]; [@R9]; [@R10]). Infection may be going away because of mass antibiotic distribution, improved hygiene, or secular changes. Regardless of the mechanism, public health stakeholders need to assess whether their programs are a success or failure. Progressive reduction of the mean prevalence of infection in a region towards zero would certainly be an encouraging trend. However, monitoring large numbers of villages longitudinally can take up scarce resources, and has not been done consistently outside a few research programs. Programs would benefit if cross-sectional surveys alone could reveal whether infection was headed towards elimination.

Mathematical models of infectious disease transmission suggest that as a disease disappears, the only stationary distribution for the expected prevalence of infection occurs when elimination has been achieved in all communities([@R11]). However, the distribution of the prevalence in those communities where infection still remains may approach a quasi-stationary distribution ([@R12]; [@R13], [@R14]). In stochastic Susceptible-Infectious-Susceptible (SIS) models, this quasi-stationary distribution can be approximated by a geometric distribution ([@R12]; [@R13], [@R14]). Specifically, if we assume a reproduction number at invasion (*R*~0~) distinctly less than one, and a refuge of one permanently infected individual in each community, then the number of infections in a set of uniform, fixed-size communities approaches a geometric distribution as the population size of communities gets larger ([@R14]). Simulations suggest that even with moderate population sizes, the geometric distribution or its continuous analog, the exponential distribution, are excellent approximations ([@R13], [@R14]; [@R15]). This has been found for models of infection disappearing due to low transmission or due to repeated mass antibiotic distributions ([@R13]; [@R15]). Note that these models typically have assumed homogeneity within and between communities ([@R16]; [@R17]). Thus, the geometric distribution may or may not fit well to field data, where these assumptions would likely not strictly hold.

Recent trachoma surveys have assessed the prevalence of infection in multiple communities biannually over several years. In each study, communities were participating in an intensive treatment program, and infection was documented to be decreasing over time. If the underlying conditions which promote transmission are similar enough in an area, then each community could be regarded as a separate sampling from a single distribution. Here, we test the hypothesis that a geometric distribution describes the prevalence of infection in different communities where infection is disappearing.

2. Methods {#S2}
==========

We considered results from the TEF study in Gurage, Ethiopia, and the TANA study in Amhara Ethiopia; in each, children from 24 communities were longitudinally monitored for ocular chlamydial infection ([@R4]; Gebre et al., 2011; [@R18]; [@R19]; [@R20]). Children are considered a core-group for ocular chlamydia infection and are therefore the most important population to monitor ([@R4]). In the TEF study, 1--5 year-old children were monitored biannually from randomly selected communities treated biannually for 2 years ([@R19]). In the TANA study, 0--9 year-old children were monitored biannually from randomly selected communities treated annually or biannually for 42 months ([@R6]). In order to characterize the distribution of infection when infection is disappearing, we included cross-sectional visits after at least two mass antibiotic distributions and where the mean prevalence of infection was lower than seen 12 months previously ([@R3]; [@R22]). For display purposes only, we produced an empirical distribution of each cross-sectional survey by assuming that each community's contribution was the Bayesian posterior derived from the observed prevalence and a non-informative, uniform prior (thus a beta distribution). To assess possible geographical clustering in TANA, where GPS coordinates were available, we conducted a permutation test of Moran's I defining neighboring communities as those sharing a vertex in a Delaunay triangulation.

For each of the cross-sectional surveys of prevalence, we assessed the fit of 8 discrete distributions. Three had a single continuous parameter: the geometric, binomial, and Poisson distributions. Four had two continuous parameters, and with the appropriate shape parameter included the geometric distribution as a special case: discrete Weibull, negative binomial, beta binomial (at least asymptotically approaching a geometric distribution as the population size increases), the zero-inflated geometric, and the zero-inflated Poisson distributions ([@R23]). Several cross-sectional surveys were available for each of the two studies. In order to combine data from the available visits, for each of the 2-parameter distributions we fitted a single overall shape parameter per study, but a different scale parameter for each available time point (of which there were 3 in TEF and 4 in TANA). Note that we chose to parameterize the zero-inflated geometric and Poisson allowing a different proportion of zeros at each visit, but a single geometric scale parameter for all visits (see Appendix). As a sensitivity analysis for the 2-parameter distributions, we fitted each cross-sectional survey separately, allowing a unique shape and scale parameter for each cross-sectional visit. Since the 24 different communities in each of the two studies had differing numbers of individuals, we parameterized such that the fitted scale parameter for each cross-sectional survey represented the mean proportion of the distribution; note that this mean proportion of the distribution was not necessarily the mean proportion of the data ([Appendix A](#APP1){ref-type="app"}). Since post-treatment distributions were right-tailed, the first shape parameter of the beta binomial distribution was treated as the shape parameter, and the second shape parameter as the scale parameter (see reparameterizations in the Appendix). Each distribution was assessed by determining the parameter values that optimized the likelihood of the observed data, and ranked by the sample size-corrected Akaike Information Criterion (AIC~c~) ([@R24]). The uncertainty of the parameter estimates was assessed with bias-corrected 95% percentile bootstrap confidence intervals with 999 resamples. We performed goodness-of-fit testing with the chi-squared statistic, binning prevalence into 5% intervals and comparing versus the geometric distribution with the optimum scale parameter. We determined the *P*-value for the observed data by selecting 999 samples from the best-fit geometric distribution for each study visit, and treated each sample in the same manner as the observed data.

As sensitivity analyses, we fitted pre-treatment data from the two study regions before a program was initiated (time 0 months in [Table 1](#T3){ref-type="table"} and the black curves in [Fig. 1 and b](#F1){ref-type="fig"}); infection was not thought to be disappearing, and thus a geometric distribution was not expected. In addition, we estimated community prevalence from a stochastic SIS model, assuming *R*~0~ = 0.5 (infection disappearing), *R*~0~ = 1.0, *R*~0~ = 1.5, or *R*~0~ = 2.0 (infection not disappearing), and creating a sample of 50 children from each of 24 communities ([@R25]). We determined the quasi-stationary distribution of the prevalence of infection pre-treatment by constructing an *N* × *N* matrix representing the *N* Kolmogorov forward equations without the zero state; the eigenvector associated with the largest eigenvalue of this matrix was taken as the quasi-stationary distribution([@R11]; [@R13]; [@R15]). The quasi-stationary distribution after three annual mass distributions with 80% coverage was estimated with 1000 simulations. In order to assess whether 24 communities were sufficient to distinguish between different distributions, we fitted multiple samples of 24 simulated communities from geometric and discrete Weibull distributions. All calculations were performed in *Mathematica* 9.0 (Wolfram Research, Champaign, Illinois).

Data were from studies registered with ClinicalTrials.gov (NCT00221364 and NCT00322972) and approved by the National Ethics Review Committee of the Ethiopian Science and Technology Agency and the UCSF IRB (10-02630 and 10-02576).

2.1. Role of the funding source {#S3}
-------------------------------

The sponsors of the study had no role in trial design, data collection, data analysis, data interpretation, or writing of the report. TL had full access to all the data in the study and had final responsibility for the decision to submit for publication.

3. Results {#S4}
==========

Visits from the two studies were included if communities had received at least two mass antibiotic distributions and if the infection was documented to have decreased from 12 months earlier were included. The 2 and 6 month visits from TEF and the 6 and 12 month visits from TANA were excluded because they were after a single treatment. The post-treatment mean prevalence of infection in the two studies varied from 1.5% to 10.9% ([Table 1](#T3){ref-type="table"}), decreasing after mass treatment. Density plots of the community-level prevalence over time are displayed in [Fig. 1](#F1){ref-type="fig"}. In TANA, where GPS was available, we were unable to demonstrate statistically significant geographical clustering for any post-treatment visit (Moran's I: *P* = 0.32 for 18 months, *P* = 0.30 for 24 months, *P* = 0.14 for 30 months, *P* = 0.64 for 36 months).

We determined the parameter values which maximized the likelihood of obtaining the observed data for the 7 distributions: geometric, binomial, Poisson, discrete Weibull, negative binomial, beta binomial, zero-inflated geometric, and zero-inflated Poisson distributions ([Table 2](#T4){ref-type="table"}). In each case, the geometric distribution had the lowest (best) AIC~c~. The binomial and Poisson distributions were the other single parameter distributions tested and offered far lower (worse) likelihoods. Note that the geometric distribution is a special case of the two-parameter distributions: discrete Weibull, negative binomial, and beta binomial (at least asymptotically), and the zero-inflated geometric distributions; thus with appropriate parameter choices, each can mimic a geometric distribution and achieve a likelihood of the observed data as least as high as that found with the geometric (with the exception of the zero-inflated geometric since we chose to use a single geometric scale parameter for each cross-sectional survey in a study, allowing the proportion that were zero to vary at each time point). Since none of these two-parameter distributions offered a significantly better fit than the geometric, the AICc was larger for these distributions. This suggests that these two-parameter distributions are less parsimonious than the geometric. The 95% confidence intervals for the estimation of the shape parameters for these two-parameter distributions included one, which in these parameterizations were consistent with the geometric ([Table 2](#T2){ref-type="table"}). Note that when we treated each individual cross-sectional survey separately allowing the shape parameter to vary with each visit, either the geometric or the zero-inflated geometric had the best AICc (for individual TANA visits, see [Appendix B](#APP2){ref-type="app"}); the 95% CIs of shape parameter of the other three 2-parameter distributions included one for each separate visit. If the community-level prevalence of infection were indeed from a geometric distribution, how often would we have found results as close to a geometric as observed? With goodness-of-fit testing, we were unable to reject the hypothesis that the observed data from each entire study, or from any single post-treatment visit within a study, came from a geometric distribution ([Table 1](#T1){ref-type="table"}).

As sensitivity analyses, simulations of an SIS model with mass action and *R*~0~ = 0.5 were used to construct a dataset similar to the Ethiopian data with 24 communities evaluated at 4 different time points. The geometric offered the optimal AICc, and in no case did the addition of a second parameter result in a statistically superior fit (likelihood ratio test, *P* \> 0.05). Similar sized sets of communities simulated from discrete Weibull distributions with shape parameters of 0.5 and 2.0 were easily distinguishable from the geometric (*P* \< 0.05), with the Weibull distribution having the optimal AICc. The model selection process correctly identified samples taken from discrete Weibull distributions with shape parameters 0.5 and 2.0. Empirical, pre-treatment surveys from the two Ethiopian areas studied were not consistent with a geometric distribution ([Table 2](#T2){ref-type="table"}). Simulations of an SIS model with mass action and *R*~0~ = 1.0, 1.5, and 2.0 (without treatment) were used to construct datasets similar to the Ethiopian data with 24 communities evaluated at 4 different time points. In all cases, the Poisson and the binomial distribution each had a far lower (better) AICc than the geometric distribution. Similar sets with an estimated treated reproduction number of *R~t~* = 1.0, 1.5, and 2.0 also were better fit by the Poisson and binomial than the geometric (for *R~t~* = 1.0 see [Appendix C](#APP3){ref-type="app"}).

4. Discussion {#S5}
=============

When assessing whether an infectious disease is on its way to elimination, survey of infection in every community in a region over time may be infeasible due to the costs of collection and processing. However, if the community-level cross-sectional prevalence of infection in an area can be approximated by a geometric distribution, then a single cross-sectional sampling of communities can provide an accurate assessment of infection in an area. Here, we assessed two large, population-based surveys recently performed in multiple communities in controlled settings where transmission conditions were similar and constant, and where trachoma was known to be disappearing due to programmatic activity. In each case, the geometric distribution fitted the observed data better than the other distributions tested. Furthermore, we were unable to reject the hypothesis that each prevalence was drawn independently from a geometric distribution in these two settings where trachoma was known to be disappearing. Much of the distributional information available from examining every community is captured by the single, sufficient parameter of a geometric distribution.

Since a geometric distribution has a relatively heavy tail, outliers are to be expected. While we cannot discount the possibility that a high prevalence village has inherently higher transmission than its neighbors, this need not be hypothesized; occasional high prevalence communities are to be expected even from a set of communities with identically transmission characteristics, and do not necessarily reflect a hot spot for transmission or a program failure. Models predict that infection will still disappear from the high prevalence communities in the tail of this distribution ([@R15], [@R17]). Empirical studies support this. Reports from Nepal, Tanzania, and the Gambia have found that the prevalence of infection in the most severely affected village *in an otherwise hypo-endemic area* decreases in the absence of treatment ([@R10]; [@R26]; [@R27]; [@R28]). Longitudinal studies that focused on the most severely affected community in an area may have led researchers to interpret this regression to the mean as enhanced efficacy of antibiotics and other interventions, relative to studies which included a control group (Gebre et al., 2011; [@R26]; [@R27]; [@R29]; [@R30]).

Recent models fitted to data from areas moderately endemic for trachoma suggest the possibility of positive feedback ([@R25]); that is, additional infection in a community may increase the per-susceptible risk of infection more than the proportional increase assumed by the mass-action model. In meso-endemic areas this may result in a bi-modal distribution of prevalence, with a peak at elimination, and a second peak around an endemic equilibrium ([@R25]). Note though that even a positive (or negative) feedback model should behave as a mass-action SIS model at a low enough prevalence, and thus the geometric distribution would still be expected. We would expect a mixture of two distributions if a survey area included distinct areas of low and high transmission. If the unit of the survey was not a single community, but a cluster of communities, we would expect the convolution of several geometric distributions (i.e. a negative binomial distribution with a shape parameter greater than one).

There are many limitations of this study. These 2--4 years longitudinal studies show decrease in prevalence, but do not follow to complete elimination. The goodness-of-fit testing assumes independent sampling from an identical distribution; while the samples were exchangeable, there may be geographical correlations. None of the sentinel communities in either TEF or TANA were contiguous, and in TANA, where GPS was available, we were unable to demonstrate any significant geographical clustering. Note that any correlation would have made it more difficult to exclude a geometric distribution, hence in that sense our analysis was conservative. Likewise, the prevalence of infection in treatment arms in TANA was not significantly different; separation by treatment arm would have resulted in smaller datasets and more difficult exclusion of the geometric distribution.

The endgame for disease control offers special challenges. While districts or subdistricts may meet thresholds for control, concern for missing higher prevalence communities has led some to argue that programs need to examine every community. Knowledge that community-level prevalence approximates a geometric distribution, and that the scale of the distribution can be estimated from a survey sample, may allow programs the confidence they need to conserve resources. Population-based surveys of all communities in trachoma-endemic areas would be an enormous undertaking, and appears to be unnecessary. Programs can assess whether they are on track towards elimination by a single cross-sectional survey. If the distribution of the community prevalence of infection in a particular area is consistent with a geometric distribution, this may be a good sign, since this would not be expected in areas where infection is not disappearing ([@R14]; [@R25]). Note that elimination would only be expected to eventually occur if conditions remain the same. An increase in transmission due to discontinuation of programmatic activity of deterioration of socioeconomic status could prevent elimination. Additional studies will be necessary to determine whether the prevalence of the clinical signs of infection on which programs rely so heavily can also be approximated by a geometric distribution.

Can trachoma be eradicated? The strains of chlamydia that cause the disease are only transmitted between humans. No vaccine has been shown efficacious. While the WHO recommends hygiene and latrine programs, no non-antibiotic measure has yet been proven to decrease infection ([@R7]; [@R29]). Mass antibiotics distributions have proven effective in cluster-randomized trials, and have so far been well tolerated ([@R2]; [@R3]; [@R4]). Trachoma has been disappearing in some areas, even in the absence of a dedicated trachoma program ([@R9]; [@R10]; [@R31]). This report suggests that if efforts are continued, infection will eventually disappear in previously hyper-endemic areas of Ethiopia. If these are representative of other severely affected regions, if trachoma programs can be maintained, and if antibiotic resistance does not evolve, then global eradication of trachoma may indeed be feasible.

This work was supported by NIH U10 EY016214, NIH GM 087728 (MIDAS), the Harper-Inglis Trust, That Man May See, and Research to Prevent Blindness.

The discrete distributions were parameterized such that the prevalence of infection would not, on average, be affected by that community's population size; the scale parameter which was maximized was the probability of an individual being infected at that cross-sectional survey, in that study. The 2-parameter distributions, were parameterized such that the shape parameter would be the same for all visits, and would equal one when the distribution represented a geometric distribution (asymptotically in the case of the beta binomial distribution). The probability mass functions used are: Geometric distribution: $\frac{\left( {1 - \frac{1}{1 + n_{j}p_{t}}} \right)^{i}}{1 + n_{j}p_{t}}\frac{\left( {1 - \frac{1}{1 + n_{j}p_{j}}} \right)^{i}}{1 + n_{j}p_{j}}$Poisson distribution: $\frac{e^{- np_{j}}\left( {n_{j}p_{j}} \right)^{i}}{i!}\frac{e^{- n_{j}p_{j}}\left( {n_{j}p_{t}} \right)^{i}}{i!}$Binomial distribution: ${(1 - p_{t})}^{- i + n_{j}}p_{t}^{i}\begin{pmatrix}
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\end{matrix} \right.$ where α is the reparameterized shape parameter, *t* is the time point, *j* is the community, *p~t~* is the mean prevalence of the distribution for the time point *t*, *n~j~* is the number of individuals in the *j*th community, and *i* is the number infected in the community. For the two zero-inflated distributions, we allowed the shape parameter to vary between visits, keeping the prevalence parameter constant.

###### 

Model fitting for individual visits of TANA, ranked by AICc of models for that visit. The best-fit shape and scale parameters are included.

  Visit            AICc     Distribution              Parameters   logLikelihood   Shape   Scale
  ---------------- -------- ------------------------- ------------ --------------- ------- -------
  TANA baseline    173.55   Negative Binomial         5            --80.107        8.352   0.395
                   187.12   Discrete Weibull          5            --86.894        1.345   1.000
                   190.30   Poisson                   4            --90.097        0.397   
                   193.53   Zero-inflated Poisson     5            --90.097        0.397   0.000
                   193.72   Geometric                 4            --91.809        0.395   
                   196.95   Zero-inflated Geometric   5            --91.809        0.395   0.000
                   218.73   Binomial                  4            --104.314       0.397   
  TANA 18 months   105.21   Geometric                 4            --47.551        0.043   
                   108.16   Discrete Weibull          5            --47.411        1.101   0.051
                   108.19   Negative Binomial         5            --47.429        1.270   0.043
                   108.44   Zero-inflated Geometric   5            --47.551        0.043   0.000
                   117.63   Zero-inflated Poisson     5            --52.150        0.054   0.204
                   120.70   Poisson                   4            --55.297        0.043   
                   122.78   Binomial                  4            --56.338        0.043   
  TANA 24 months   96.71    Geometric                 4            --43.304        0.036   
                   99.48    Zero-inflated Poisson     5            --43.071        0.053   0.327
                   99.84    Discrete Weibull          5            --43.256        1.066   0.040
                   99.87    Negative Binomial         5            --43.270        1.160   0.036
                   99.91    Zero-inflated Geometric   5            --43.287        0.037   0.034
                   106.46   Poisson                   4            --48.179        0.036   
                   107.53   Binomial                  4            --48.711        0.036   
  TANA 30 months   67.88    Geometric                 4            --28.885        0.015   
                   69.92    Zero-inflated Poisson     5            --28.294        0.032   0.529
                   70.40    Zero-inflated Geometric   5            --28.532        0.020   0.257
                   70.66    Negative Binomial         5            --28.663        0.590   0.015
                   70.72    Discrete Weibull          5            --28.695        0.855   0.013
                   73.47    Poisson                   4            --31.681        0.015   
                   73.80                              4            --31.847        0.015   
  TANA 36 months   85.71    Geometric                 4            --37.804        0.026   
                   88.33    Zero-inflated Geometric   5            --37.499        0.032   0.173
                   88.39    Discrete Weibull          5            --37.530        0.853   0.021
                   88.41    Negative Binomial         5            --37.539        0.655   0.026
                   90.82    Zero-inflated Poisson     5            --38.745        0.047   0.440
                   99.13    Poisson                   4            --44.511        0.027   
                   100.16   Binomial                  4            --45.028        0.027   

###### 

Model fitting for individual visits of simulated SIS model, ranked by AICc of models for that visit. The best-fit shape and scale parameters are included. Parameters for the model include: population of 50 children per community, *R*~0~ = 2.6 (in the absence of treatment), estimated *R~t~* = 1.0 (in the presence of treatment)([@R32]), 80% coverage with 100% effective antibiotic, rate of recovery 1/52 weeks.

  Visit                 AICc     Distribution              Parameters   Log Likelihood   Shape      Scale
  --------------------- -------- ------------------------- ------------ ---------------- ---------- -------
  Simulated baseline    148.55   Poisson                   1            −73.183                     0.395
                        150.94   Zero-inflated Poisson     2            −73.183          0.572      1.000
                        150.94   Negative Binomial         2            −73.183          1120,000   0.397
                        159.10   Binomial                  1            −78.462                     0.000
                        206.20   Discrete Weibull          2            −100.814         1.223      0.395
                        212.02   Geometric                 1            −104.917                    0.000
                        214.41   Zero-inflated Geometric   2            −104.917         0.573      0.397
  Simulated 18 months   151.41   Negative Binomial         2            −73.419          4.261      0.043
                        151.66   Discrete Weibull          2            −73.546          1.669      0.051
                        160.52   Zero-inflated Poisson     2            −77.972          0.197      0.043
                        160.49   Geometric                 1            −79.152                     0.000
                        162.87   Zero-inflated Geometric   2            −79.152          0.189      0.204
                        169.14   Poisson                   1            −83.477                     0.043
                        179.79   Binomial                  1            −88.804                     0.043
  Simulated 24 months   165.43   Negative Binomial         2            −80.429          3.944      0.036
                        167.17   Discrete Weibull          2            −81.297          1.506      0.327
                        174.50   Geometric                 1            −86.161                     0.040
                        176.89   Zero-inflated Geometric   2            −86.161          0.257      0.036
                        182.11   Zero-inflated Poisson     2            −88.769          0.268      0.034
                        197.62   Poisson                   1            −97.720                     0.036
                        222.16   Binomial                  1            −109.989                    0.036
  Simulated 30 months   174.68   Negative Binomial         2            −85.053          4.651      0.015
                        179.35   Discrete Weibull          2            −87.390          1.401      0.529
                        185.06   Zero-inflated Poisson     2            −90.243          0.345      0.257
                        186.29   Geometric                 1            −92.052                     0.015
                        188.68   Zero-inflated Geometric   2            −92.052          0.331      0.013
                        208.15   Poisson                   1            −102.983                    0.015
                        241.48   Binomial                  1            −119.651                    0.015
  Simulated 36 months   111.89   Discrete Weibull          2            −53.662          1.802      0.026
                        112.17   Negative Binomial         2            −53.799          5.766      0.173
                        112.64   Zero-inflated Poisson     2            −54.033          0.078      0.021
                        112.64   Poisson                   1            −55.229                     0.026
                        113.73   Binomial                  1            −55.775                     0.440
                        118.57   Geometric                 1            −58.193                     0.027
                        120.96   Zero-inflated Geometric   2            −58.193          0.073      0.027

![(a) Distribution of the prevalence of ocular chlamydia infection in 1-5 year-old children in 24 communities in the TEF study, Gurage, Ethiopia. ([@R19]) Communities were treated biannually with mass oral azithromycin. The distribution of infection for each cross-sectional survey is displayed as a density plot, in which each community's contribution is the Bayesian posterior derived from the observed prevalence and a non-informative, uniform prior. The prevalence clearly decreases from baseline (black curve) to post-treatment visits at 12, 18, and 24 months (progressively lighter grey curves). (b) Distribution of the prevalence of ocular chlamydia infection in 0--9 year-old children in 24 communities in the TANA study, Amhara, Ethiopia. ([@R6]) Communities were treated annually or biannually. The prevalence decreases from baseline (black curve) to post-treatment visits at 18, 24, 30, and 36 months (progressively lighter grey curves).](nihms807799f1){#F1}

###### 

Prevalence of ocular chlamydial infection in longitudinal studies of trachoma in Ethiopia.

                  Prevalence of Infection                   
  --------------- ------------------------- ------- ------- ------
  TEF Ethiopia                                              
   0 Months       16                        0.529   0.218   0.03
   12 Months      16                        0.069   0.109   0.23
   18 Months      16                        0.032   0.037   0.58
   24 Months      16                        0.020   0.022   0.30
  TANA Ethiopia                                             
   0 Months       24                        0.394   0.153   0.03
   18 Months      24                        0.043   0.050   0.29
   24 Months      24                        0.036   0.041   0.12
   30 Months      24                        0.015   0.025   0.89
   36 Months      24                        0.026   0.037   0.74

###### 

Model fit of the distribution of the community-level prevalence of infection in Ethiopian trachoma studies.

  TEF 12, 18, and 24 months            Shape parameter          No. of parameters       Log~e~ Likelihood       AIC~c~
  ------------------------------------ ------------------------ ----------------------- ----------------------- ------------
  **Geometric**                                                 4                       −125.79                 263.576
  **Negative binomial**                0.824 (0.364 to 1.663)   5                       −125.58                 265.165
  **Beta binomial**                    0.742 (0.335 to 1.526)   5                       −125.76                 265.528
  **Discrete Weibull**                 0.999 (0.750 to 1.289)   5                       −125.79                 265.580
  **Zero-inflated Geometric**          0.956 (0.934 to 0.972)   5                       −130.91                 275.815
  **Poisson**                                                   4                       −153.42                 318.838
  **Binomial**                                                  4                       −157.68                 327.356
  **TANA 18, 24, 30, and 36 months**   **Shape parameter**      **No. of parameters**   **Log~e~ Likelihood**   **AIC~c~**
  **Geometric**                                                 5                       −157.544                329.089
  **Beta binomial**                    0.926 (0.674 to 1.412)   6                       −157.435                330.871
  **Negative binomial**                0.960 (0.462 to 1.820)   6                       −157.535                331.070
  **Zero-inflated Geometric**          0.957 (0.935 to 0.976)   6                       −157.894                331.788
  **Discrete Weibull**                 1.030 (0.792 to 1.363)   6                       −158.390                332.779
  **Poisson**                                                   5                       −179.668                373.335
  **Binomial**                                                  5                       −181.924                377.849
